Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Based on the positive findings of the INAVO120 study, inavolisib is the only phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor approved for breast cancer treatment in China and has been included in the National Reimbursement Drug List following national medical insurance price negotiations. Methods A partitioned survival model with a 30-year time horizon was constructed to assess the cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant alone in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)-, locally advanced or metastatic breast cancer (a/m BC). Clinical data were extracted from the Asian cohort of the INAVO120 trial. Drug prices were sourced from the government procurement platform, while additional cost and utility parameters were derived from the published literature. The primary model outcome was the incremental cost-effectiveness ratio (ICER). To assess the robustness of the results, scenario and sensitivity analyses were performed. Additionally, a price simulation analysis was conducted for inavolisib. Results The ICER was determined to be $36,932.91/quality-adjusted life-year (QALY), which exceeded the willingness-to-pay (WTP) threshold of $27,906/QALY. To attain cost-effectiveness, a further price reduction of 27.02% for inavolisib would be necessary. Scenario and sensitivity analyses confirmed the robustness of the results. Conclusion The addition of inavolisib to palbociclib plus fulvestrant for PIK3CA-mutated HR+/HER2-a/m BC is not a cost-effective treatment strategy at the national level in China. However, this triple therapy may achieve cost-effectiveness in economically affluent regions with higher local WTP thresholds.